Sabine D. Brookman-May, Professor of Urology at München University, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Sima Porten presents in AUC3: BCG still works — if patients can stay on it. Increased adherence, better side effects management, upfront immune priming, complementary mechanisms can improve efficacy smarter biomarkers might support selection of patients who respond better to BCG.”
More posts about Bladder Cancer.